CompareMarketResearchRequest a sample
Home / Healthcare / Diagnostic Exosome Biomarkers

Healthcare · Market report

Diagnostic Exosome Biomarkers Market Size, Share and Forecast 2026-2036

The global diagnostic exosome biomarkers market is worth USD 242 mn in 2026 and is forecast to reach USD 977 mn by 2036, growing at a 15.0% CAGR. United States is the largest country market and Isolation kits and reagents is the largest by product segment.

USD 242 mnMarket size 2026
USD 977 mnForecast 2036
15.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global diagnostic exosome biomarkers market is worth USD 242 mn in 2026 and is forecast to reach USD 977 mn by 2036, growing at a 15.0% CAGR. United States is the largest country market and Isolation kits and reagents is the largest by product segment.

ScopeTests and tools based on exosomes and other extracellular vesicles: isolation kits and reagents, diagnostic assays for cancer and other disease, instruments and biomarker services.
IndustryHealthcare
Value 2025USD 210 mn
Value 2026USD 242 mn
Value 2036USD 977 mn
CAGR 2026-203615.0%
Volume 2026906 thousand assays
Volume 20364,053 thousand assays
Average price 2026USD 266 per assay
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Diagnostic Exosome Biomarkers market size and forecast, 2026-2036

Exhibit 1The global diagnostic exosome biomarkers market is forecast to grow from USD 242 mn in 2026 to USD 977 mn by 2036, more than triplingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 15.0%
Diagnostic Exosome Biomarkers market value, 2025 to 2036Market value by year. 2025: USD 210 mn; 2026: USD 242 mn; 2027: USD 278 mn; 2028: USD 319 mn; 2029: USD 367 mn; 2030: USD 422 mn; 2031: USD 486 mn; 2032: USD 559 mn; 2033: USD 642 mn; 2034: USD 739 mn; 2035: USD 850 mn; 2036: USD 977 mn. Compound annual growth rate 2026 to 2036: 15.0%.2025242 mn2026486 mn2031977 mn203615.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 242 mn
2027USD 278 mn
2028USD 319 mn
2029USD 367 mn
2030USD 422 mn
2031USD 486 mn
2032USD 559 mn
2033USD 642 mn
2034USD 739 mn
2035USD 850 mn
2036USD 977 mn

Diagnostic Exosome Biomarkers market segmentation

By product

Exhibit 2Isolation kits and reagents is the largest segment by product, with 44.0% of 2026 revenueEstimated share of 2026 global revenue, by product
Diagnostic Exosome Biomarkers market share by product, 2026Share of 2026 revenue by product. Isolation kits and reagents: 44.0%; Diagnostic assays: 30.0%; Instruments: 14.0%; Biomarker services: 12.0%.Isolation kits and reagents44.0%Diagnostic assays30.0%Instruments14.0%Biomarker services12.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Isolation kits and reagents44.0%31.1%USD 106 mn11.1%
Diagnostic assays30.0%46.0%USD 72 mn20.0%
Instruments14.0%10.8%USD 34 mn12.1%
Biomarker services12.0%12.1%USD 29 mn15.1%

By use

Exhibit 3Clinical diagnostics adds the most revenue by use, growing from USD 87 mn in 2026 to USD 508 mn by 2036Estimated revenue in USD by use, 2026 and 2036 forecast
Diagnostic Exosome Biomarkers market by use, 2026 and 2036Revenue by use in 2026 and 2036. Clinical diagnostics: USD 87 mn in 2026, USD 508 mn in 2036, change +484%; Research use: USD 126 mn in 2026, USD 368 mn in 2036, change +193%; Pharma biomarker development: USD 29 mn in 2026, USD 101 mn in 2036, change +250%.20262036 forecastChangeClinical diagnostics+484%87 mn508 mnResearch use+193%126 mn368 mnPharma biomarker development+250%29 mn101 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Research use52.0%37.7%USD 126 mn11.3%
Clinical diagnostics36.0%52.0%USD 87 mn19.3%
Pharma biomarker development12.0%10.4%USD 29 mn13.3%

By vesicle source

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Blood and plasma42.0%40.0%USD 101 mn14.4%
Urine26.0%26.0%USD 63 mn15.0%
Saliva and others16.0%17.0%USD 39 mn15.7%
Cell culture media16.0%17.0%USD 39 mn15.7%

By biomarker

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
RNA based34.0%36.0%USD 82 mn15.7%
Protein based38.0%36.0%USD 92 mn14.4%
DNA and lipid28.0%28.0%USD 68 mn15.0%

By disease

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Cancer58.0%56.0%USD 140 mn14.6%
Neurological16.0%18.0%USD 39 mn16.4%
Cardiovascular12.0%12.0%USD 29 mn15.0%
Others diseases14.0%14.0%USD 34 mn15.0%

Top 25 countries for diagnostic exosome biomarkers by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 89.0% of 2026 revenue and the 25 countries below together hold 97.2%.

Exhibit 4United States is the largest country market at USD 97 mn in 2026, and the three largest countries hold 62.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Diagnostic Exosome Biomarkers market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 97 mn, 40.0%; China: USD 39 mn, 16.0%; Germany: USD 14 mn, 6.0%; Japan: USD 14 mn, 6.0%; United Kingdom: USD 12 mn, 5.0%; South Korea: USD 12 mn, 5.0%; France: USD 7.2 mn, 3.0%; Canada: USD 7.2 mn, 3.0%; India: USD 7.2 mn, 3.0%; Italy: USD 4.8 mn, 2.0%.United States97 mn 40.0%China39 mn 16.0%Germany14 mn 6.0%Japan14 mn 6.0%United Kingdom12 mn 5.0%South Korea12 mn 5.0%France7.2 mn 3.0%Canada7.2 mn 3.0%India7.2 mn 3.0%Italy4.8 mn 2.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 97 mn40.0%USD 382 mn14.7%
2ChinaUSD 39 mn16.0%USD 182 mn16.7%
3GermanyUSD 14 mn6.0%USD 53 mn13.8%
4JapanUSD 14 mn6.0%USD 50 mn13.2%
5United KingdomUSD 12 mn5.0%USD 46 mn14.3%
6South KoreaUSD 12 mn5.0%USD 52 mn15.7%
7FranceUSD 7.2 mn3.0%USD 26 mn13.8%
8CanadaUSD 7.2 mn3.0%USD 27 mn14.2%
9IndiaUSD 7.2 mn3.0%USD 37 mn17.8%
10ItalyUSD 4.8 mn2.0%USD 17 mn13.2%
11SwitzerlandUSD 3.2 mn1.3%USD 13 mn14.7%
12NetherlandsUSD 3.2 mn1.3%USD 12 mn14.6%
13AustraliaUSD 2.4 mn1.0%USD 9.7 mn14.8%
14SpainUSD 1.9 mn0.8%USD 7.4 mn14.7%
15SwedenUSD 1.9 mn0.8%USD 7.3 mn14.7%
16DenmarkUSD 1.4 mn0.6%USD 5.8 mn14.8%
17BelgiumUSD 1.1 mn0.5%USD 4.4 mn14.8%
18BrazilUSD 0.94 mn0.4%USD 4.2 mn16.1%
19TaiwanUSD 0.80 mn0.3%USD 3.5 mn16.0%
20IsraelUSD 0.65 mn0.3%USD 2.6 mn15.0%
21AustriaUSD 0.65 mn0.3%USD 2.6 mn15.0%
22SingaporeUSD 0.60 mn0.2%USD 2.6 mn15.9%
23PolandUSD 0.43 mn0.2%USD 1.9 mn15.6%
24MexicoUSD 0.39 mn0.2%USD 1.8 mn16.4%
25RussiaUSD 0.36 mn0.1%USD 1.6 mn15.7%
Rest of worldUSD 6.6 mn2.8%USD 25 mn14.3%
Exhibit 5United States and China account for 58% of the USD 736 mn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Diagnostic Exosome Biomarkers market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 242 mn. United States: +USD 285 mn; China: +USD 143 mn; South Korea: +USD 40 mn; Germany: +USD 38 mn; Japan: +USD 35 mn; 20 other countries: +USD 175 mn; Rest of world: +USD 19 mn. Market value 2036: USD 977 mn.Market value 2026242 mnUnited States+285 mnChina+143 mnSouth Korea+40 mnGermany+38 mnJapan+35 mn20 other countries+175 mnRest of world+19 mnMarket value 2036977 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Bio-Techne
  • Thermo Fisher Scientific
  • Qiagen
  • Bio-Rad Laboratories

Group 2: Regional and specialist players

  • Miltenyi Biotec
  • System Biosciences
  • Norgen Biotek
  • Malvern Panalytical
  • Particle Metrix

Group 3: Emerging and niche players

  • HansaBioMed
  • Izon Science
  • Mursla Bio
  • Exosomics
  • ONI
  • Creative Biolabs

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the diagnostic exosome biomarkers market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 15.0% is calculated from the resulting values.

The market is divided by product, by use, by vesicle source, by biomarker, by disease. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the diagnostic exosome biomarkers market?

The global diagnostic exosome biomarkers market is estimated at USD 210 mn in 2025 and USD 242 mn in 2026.

How fast will the diagnostic exosome biomarkers market grow?

It is forecast to reach USD 977 mn by 2036, a compound annual growth rate of 15.0% from 2026, an increase of USD 736 mn.

Which country is the largest market for diagnostic exosome biomarkers?

United States is the largest market by revenue at USD 97 mn in 2026, 40.0% of the global total. The three largest countries together hold 62.0%.

Which country is growing fastest?

Among the ten largest markets, India is growing fastest at 17.8% a year from 2026 to 2036.

Which diagnostic exosome biomarkers segment is largest?

In the by product split, Isolation kits and reagents is the largest segment with 44.0% of 2026 revenue.

Who are the leading diagnostic exosome biomarkers companies?

Global leaders include Bio-Techne, Thermo Fisher Scientific, Qiagen, Bio-Rad Laboratories.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Diabetes Drugs Dietary Supplement →

All Healthcare markets →

Request a sample